Dr. Reddy’s Inks Licensing Deal Worth Up to $370M for Immutep’s Late-Stage Eftilagimod Alpha
Strengthening its oncology innovation portfolio, Dr. Reddy’s Laboratories has entered into an exclusive licensing agreement with Australian biotech Immutep to […]
